Home > Resources > Whitepapers > White Paper: Compliance with HIPAA, CLIA, dbGaP, EU Privacy, and ISO 27001 on DNAnexus

White Paper: Compliance with HIPAA, CLIA, dbGaP, EU Privacy, and ISO 27001 on DNAnexus

This White Paper summarizes how use of the DNAnexus platform supports compliance with various US and International regulations and standards. DNAnexus has a robust, audited set of policies, processes, and controls for security and privacy. Internally, DNAnexus organizes security and privacy around the internationally-accepted ISO 27001 and 27002 security standards, which provide a comprehensive framework for security and compliance. Each supported security and privacy regulation requires a subset of the DNAnexus platform’s overall security and privacy controls.

Spotlight

Hansa Biopharma

Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives.

OTHER WHITEPAPERS

Multi-Specific Monoclonal Antibodies

whitePaper | February 22, 2023

The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralise or promote its activity. The efficacy and safety.

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

whitePaper | July 25, 2022

The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics are maintained.

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations

More Whitepapers